Additional file 2: of Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
journal contributionposted on 04.12.2018 by Fatima Karzai, David VanderWeele, Ravi Madan, Helen Owens, Lisa Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane Trepel, Maria Merino, Ryan Dittamore, Jennifer MartĂŠ, Renee Donahue, Jeffrey Schlom, Keith Killian, Paul Meltzer, Seth Steinberg, James Gulley, Jung-Min Lee, William Dahut
Any type of content formally published in an academic journal, usually following a peer-review process.
A. Immunophenotyping of myeloid-derived suppressor cells (MDSCs). B. Statistical analysis of pharmacodynamic endpoints. (DOCX 18 kb)